The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium

Author

  • Eugen Kolossov
  • Toktam Bostani
  • Wilhelm Roell
  • Martin Breitbach
  • Frank Pillekamp
  • Jens Nygren
  • Philipp Sasse
  • Olga Rubenchik
  • Jochen W. U. Fries
  • Daniela Wenzel
  • Caroline Geisen
  • Ying Xia
  • Zhongju Lu
  • Yaqi Duan
  • Ralf Kettenhofen
  • Stefan Jovinge
  • Wilhelm Bloch
  • Heribert Bohlen
  • Armin Welz
  • Juergen Hescheler
  • Sten Eirik W Jacobsen
  • Bernd K. Fleischmann

Summary, in English

Cellular cardiomyoplasty is an attractive option for the treatment of severe heart failure. It is, however, still unclear and controversial which is the most promising cell source. Therefore, we investigated and examined the fate and functional impact of bone marrow (BM) cells and embryonic stem cell (ES cell)-derived cardiomyocytes after transplantation into the infarcted mouse heart. This proved particularly challenging for the ES cells, as their enrichment into cardiomyocytes and their long-term engraftment and tumorigenicity are still poorly understood. We generated transgenic ES cells expressing puromycin resistance and enhanced green fluorescent protein cassettes under control of a cardiac-specific promoter. Puromycin selection resulted in a highly purified (> 99%) cardiomyocyte population, and the yield of cardiomyocytes increased 6-10-fold because of induction of proliferation on purification. Long-term engraftment (4-5 months) was observed when co-transplanting selected ES cell -derived cardiomyocytes and fibroblasts into the injured heart of syngeneic mice, and no teratoma formation was found (n = 60). Although transplantation of ES cell-derived cardiomyocytes improved heart function, BM cells had no positive effects. Furthermore, no contribution of BM cells to cardiac, endothelial, or smooth muscle neogenesis was detected. Hence, our results demonstrate that ES-based cell therapy is a promising approach for the treatment of impaired myocardial function and provides better results than BM-derived cells.

Publishing year

2006

Language

English

Pages

2315-2327

Publication/Series

Journal of Experimental Medicine

Volume

203

Issue

10

Document type

Journal article

Publisher

Rockefeller University Press

Topic

  • Cell and Molecular Biology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1540-9538